Introduction
============

Diseases resulting from *Escherichia coli* (*E. coli*) infections, including colibacillosis, air sacculitis, and cellulitis, are responsible for high morbidity and mortality in poultry, and these diseases exert a significant economic influence on the poultry industry \[[@B1],[@B6]\].

Antimicrobials are valuable tools for the treatment of clinical disease and for the maintenance of healthy, productive animals. However, recent reports have discovered increased resistance to the antimicrobial agents commonly utilized for treatment \[[@B1],[@B4],[@B25],[@B27]\].

Florfenicol, a broad-spectrum antibiotic, belongs to the family of agents including thiamphenicol and chloramphenicol, which has played a hugely important role in reducing the enormous losses in the poultry industry resulting from certain bacterial diseases, including avian colibacillosis. However, Kim et al. \[[@B21]\] identified a novel plasmid-encoded gene (*pp-flo*) from *Photobacterium piscicda* in a study conducted in Japan \[[@B21]\]. More recently, florfenicol resistance conferred by the *floR* genes, referred to in the published literature as *pp-flo*, *cmlA*-*like*, *floSt*, *flo*, or *floR*, has also been detected in the *Salmonella enteria* serovar Typhimurium definitive phage type (DT) 104 \[[@B2],[@B3],[@B8]-[@B10],[@B20]\], *Salmonella enterica* serovar Agona \[[@B9],[@B14]\], *E. coli* \[[@B5],[@B7],[@B13],[@B15],[@B16],[@B19],[@B26]\], *Klebsiella pneumoniae* \[[@B12]\], *Vibrio cholerae* \[[@B17]\] and *Pasteurella multocida* \[[@B18]\], which mediate combined resistance to florfenicol and chloramphenicol.

Currently, very little data is available regarding the epidemiology and prevalence of antimicrobial-resistant veterinary pathogens in domestic animals, particularly in developing countries, including China, where antimicrobials are overused in veterinary medicine and domestic animals. Thus, the principal objective of the present study was to determine the antimicrobial susceptibility profiles among a collection of *E. coli* isolates collected from diseased chickens that were diagnosed with colibacillosis in China between 2004 and 2005. In addition, due to the high incidence of emerging florfenicol resistance in tested *E. coli* isolates 5 to 6 years after its introduction into veterinary clinics and the limited information regarding phenicol resistance in China, the resistance determinants for the phenotypes of phenicol resistance observed in these isolates were identified. The results presented herein may provide surveillance information for this specific region.

Materials and Methods
=====================

Bacterial strains
-----------------

70 *E. coli* isolates were recovered from the livers of diseased chickens raised on 12 different poultry farms in Henan Province, China, from January 2004 to September 2005. All *E. coli* organisms were isolated and purified on MacConkey agar and verified as *E. coli* using the Vitek system (BioMerieux, USA). The strains were maintained at -86℃ until analysis. The CVM1841 and CVM827 strains, which were used as positive controls for the amplification of the *floR* and *cmlA* genes, were kindly donated by Dr. David White of the FDA, USA. The positive strains harboring the *cat-1*, *cat-2* or *cat-3* genes were obtained from the microbiology lab at Henan Agricultural University and were designated as strain C258, strain C337, and the strain C151, respectively.

Antimicrobial susceptibility determination
------------------------------------------

Antimicrobial minimum inhibitory concentrations (MIC) of the *E. coli* isolates were determined via the standard broth doubling dilution method on Muller-Hinton medium, and were interpreted in accordance with CLSI standards \[[@B11]\]. According to the suggestions provided in a previous report by Singer et al. \[[@B23]\], florfenicol resistance breakpoints in *E. coli* might be defined by an MIC of 32 µg/ml. The following antimicrobials were tested: ampicillin, ceftiofur, chloramphenicol, florfenicol, dihydrostreptomycin, gentamicin, amikacin, kanamycin, enrofloxacin, ciprofloxacin, oxytetracycline, and trimethoprim/sulfamethoxazole (China Institute of Veterinary Control, China). *E. coli* ATCC 25922 was used as a control in all of the MIC determinations.

Detection of florfenicol and chloramphenicol-resistance determinants
--------------------------------------------------------------------

Genes encoding for florfenicol and chloramphenicol resistance determinants (*floR*, *cmlA*, *cat-1*, *cat-2*, and *cat-3*) were detected via PCR. Templates of total DNA from each isolate were prepared as previously described \[[@B5]\]. For the detection of the *floR* genes, one pair of the forward primer (flo1: 5\'-GTGTCGTCACATCTACGGCCTTT-3\') and the reverse primer (flo2: 5\'-CAGACAGGATACCGACATTC AC-3\') was designed using Oligo 6.0 software on the basis of the published *floR* gene sequence \[[@B26]\]. Between the two primers, the sequence region predicted an 882-bp fragment. For the positive control, the CVM1841 strain, which harbors the *floR* gene, was utilized. PCR was conducted in a final volume of 50 µl containing 1 µg of template DNA, 100 pmol of each primer (flo1/flo2), 1 × PCR buffer, 0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP) and 2.5 U of Ex Taq polymerase (Takara, Japan). A total of 32 cycles were conducted in the PCR Express (Thermo Hybaid, UK), under the following conditions: denaturation at 94℃ for 45 sec, annealing at 62℃ for 45 sec, and an extension step at 72℃ for 1 min.

The primer sets employed in the amplification of *cmlA*, *cat-1*, *cat-2*, and *cat-3* were identical to those previously described \[[@B19],[@B24]\]. For the amplification of the different amplicons, the appropriate program parameters were utilized. The predicted amplicons for the *cmlA*, *cat-1*, *cat-2*, and *cat-3* genes were 699, 585, 495, and 508 bp, respectively. The CVM827, C258, C337, and C151 strains were utilized as positive controls for the amplification of the *cmlA*, *cat-1*, *cat-2*, and *cat-3* genes, respectively.

Results
=======

Antimicrobial susceptibility patterns of chicken *E. coli* isolates
-------------------------------------------------------------------

Seventy *E. coli* isolates recovered from diseased chickens diagnosed with colibacillosis were tested for their resistance to 11 antimicrobial agents of human and veterinary therapeutic significance. The rates of resistance, as determined via measurements of the MIC and comparisons to the resistance breakpoints established by CLSI, are listed in [Table 1](#T1){ref-type="table"}. The highest rates of resistance were to trimethoprim-sulfamethoxazole (100%), oxytetracycline (100%), ampicillin (83%), enrofloxacin (83%), ciprofloxacin (81%), and chloramphenicol (79%), respectively.

With regard to multidrug resistance profiles, all of the isolates recovered from the diseased chickens proved resistant to more than 4 of the 11 tested antimicrobials, 93% were resistant to more than 8 antimicrobials, and 1% were resistant to all 11 of the antimicrobials. The majority of *E. coli* isolates from this study proved susceptible to ceftiofur (93%) and amikacin (88%).

Molecular detection of the florfenicol and chloramphenicol resistant deteminants
--------------------------------------------------------------------------------

The genetic mechanisms relevant to chloramphenicol and florfenicol resistance in the chicken *E. coli* isolates were evaluated for the presence of 5 genes recognized to confer resistance to these antimicrobials: *cmlA*, *cat-1*, *cat-2*, *cat-3*, and *floR*. The different amplification products for the genes encoding for florfenicol and chloramphenicol resistance determinants are provided in [Fig. 1](#F1){ref-type="fig"}. Using the total genomic DNA from each of the seventy chloramphenicol-resistant isolates as the PCR template, fifteen *E. coli* isolates (21.4%) were found to be positive for the *cmlA* gene and thirteen *E. coli* isolates (18.6%) were positive for the *floR* gene, with 20 of these isolates (28.6%) also harboring one of the chloramphenicol acetyltransferase genes (*cat-1* or *cat-2*) ([Table 2](#T2){ref-type="table"}). Additionally, seven *E. coli* isolates (10%) were found to be positive for both the *floR* and *cmlA* genes, and both florfenicol and chloramphenicol MICs for these isolates were elevated (≥64 µg/ml) ([Table 2](#T2){ref-type="table"}).

Discussion
==========

The bacterial isolates assessed in this study displayed similar levels of resistance to oxytetracycline, ampicillin, norfloxacin, and ciprofloxacin as were previously reported for *E. coli* strains isolated from diseased chickens in China by Yang et al. \[[@B27]\]. However, the chloramphenicol resistance rate (79%) determined in this study was significantly higher than that reported in the same country (24%), and this may reflect different patterns of antimicrobial use in different regions. In addition, as compared to the data from the only other report concerning florfenicol resistance in chicken *E. coli* isolates by Keyes et al. \[[@B19]\], the chicken *E. coli* isolates evaluated in this study displayed elevated resistance levels ([Table 1](#T1){ref-type="table"}).

Due to the wide use of oxytetracycline, sulfonamides, chloramphenicol, and fluoroquinolones for the treatment and prevention of diseases in chickens over the past decade, it was expected that the *E. coli* strains recovered from diseased chickens diagnosed with colibacillosis in this study would displayed a high rate of resistance to these drugs, and that was indeed the case. However, the high incidence of florfenicol resistance in the *E. coli* isolates tested herein was somewhat unexpected, as this drug was introduced into veterinary clinics for use in China only 6 to 7 years ago. This finding suggests that the selection pressure of chloramphenicol, as well as the other antimicrobials, may perform a relevant role in the emergence and dissemination of florfenicol resistance in *E. coli*.

Antimicrobials are useful therapeutic agents only if the drug concentrations achieved in the serum and tissue exceed the MIC of the drug. Based on this principle, Keyes et al. \[[@B19]\] suggested that florfenicol may not be therapeutically successful in some cases, as pharmacokinetic studies have demonstrated that the peak plasma florfenicol concentration in broiler chickens following oral administration of 15 mg/kg body weight is approximately 4 µg/ml. The florfenicol-resistant chicken *E. coli* isolates observed in both that study and the present study displayed florfenicol MICs in excess of that amount \[[@B19],[@B22]\]. In this study, we also noted that 29 percent of the total isolates displayed florfenicol MICs in excess of 32 µg/ml. In order to ensure the rational and effective use of this drug, the expanded veterinary use of this drug in the treatment of *E. coli*-related chicken diseases can not be recommended at this time.
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